AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2017
Oct 11, 2017
31920_dirs_2017-10-11_39d643fb-b0ba-4084-90b6-682a06b10f9e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2017-10-10
Reporting Person: SULLIVAN STEPHEN G. (See Remarks)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ADSs | 10000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $23.53 | 2025-09-15 | ADSs (50000) | 50000 | Direct |
| Stock Option (right to buy) | $10.4 | 2026-12-14 | ADSs (65000) | 65000 | Direct |
Footnotes
F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F2: Represents 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
F3: Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 09/15/2015 grant date.
F4: Options become exercisable as to 16,250 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.